Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

Figure 1

BT474 lapatinib-resistant cells acquire E542K PIK3CA mutation. (A) SNaPshot analysis of genomic DNA isolated from parental and lapatinib-resistant (LR) cells reveals a distinct peak corresponding to a G1624A nucleotide change in resistant cells. (B) Sanger sequencing of exon 9 of PIK3CA confirms the presence of the G1624A nucleotide change in LR cells. (C) Lysates from parental and LR cells treated with increasing doses of lapatinib, ranging from 0.001 to 10 μM, were analyzed by immunoblotting with the indicated antibodies.

Back to article page